Overview: Lipid Screen Panel
Introduction: The Lipid Screen Panel is a diagnostic tool designed to screen for lipid disorders using serum samples. In India, dyslipidemia is a leading modifiable CVD risk factor (~40-50 percent prevalence), with screening recommended for adults >30-40 years or high-risk groups to prevent premature atherosclerosis. High morbidity from under-screening in rural/low-SES populations with poor awareness, limited labs, delayed lifestyle/statin intervention leading to early MI/stroke. Per cardiology practices aligned with ICMR, Cardiological Society of India, and NPCDCS guidelines, the test employs spectrophotometry for total cholesterol, HDL, LDL, triglycerides, VLDL, and cholesterol/HDL ratio over 1-2 days with high accuracy, valuable for primary prevention and risk scoring (Framingham/QRISK). This diagnostic falls under lipid screening and targets asymptomatic adults with risk factors (obesity, diabetes, smoking), addressing accurate detection to guide diet, exercise, or statin therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early lipid disorder identification and reducing CVD burden. Its serum-based approach ensures reliable screening profile.
Other Names: Lipid Scr Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: Lipid screening standard; in India, integrated in NPCDCS.
Purpose: The test assesses 6 parameters including total cholesterol to guide lipid disorder screening, assess CVD risk, inform prevention.
Test Parameters: 1. Total Cholesterol, 2. HDL, 3. LDL, 4. Triglycerides, 5. VLDL, 6. Cholesterol/HDL Ratio.
Pretest Condition: Fasting 10-12 hours required; patients should have CVD risk factors.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on family CVD, diabetes, smoking.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected dyslipidemia including MI, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal profile indicates high CVD risk, necessitating specialist input.
Specialist Consultation: Physicians or cardiologists should be consulted for management.
Additional Supporting Tests: Non-HDL, apoB for confirmation.
Test Limitations: Fasting critical; comprehensive approach required.
References: Indian Journal of Community Medicine 2024, CVD Studies India 2023.
